Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.59 |
| ▸ | UMPS | P11172 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 16/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218084 | 0.85 | DHFR (0.58) | DHFRSTING1 | |
| SCHEMBL3490221 | 0.85 | DHFR (0.58) | DHFRUMPSSTING1 | |
| SCHEMBL3203326 | 0.83 | DHFR (0.56) | DHFRSTING1 | |
| SCHEMBL3219336 | 0.81 | UMPS (0.52) | UMPSSTING1 | |
| SCHEMBL2408425 | 0.77 | DHFR (0.75) | DHFRSTING1 | |
| SCHEMBL3225428 | 0.75 | DHFR (0.62) | DHFRSTING1 | |
| SCHEMBL1619438 | 0.74 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL16558263 | 0.74 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL3215086 | 0.73 | DHFR (0.56) | DHFRSTING1 | |
| SCHEMBL3218886 | 0.72 | LMNA (0.56) | UMPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | claimed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | DHFR 5/4885UMPS 17/4885STING1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.